SYROS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.04 USD | -1.18% |
|
+11.01% | -35.30% |
| 04-09 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| 04-09 | Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise | MT |
| Sales 2024 * | 2.8M 3.83M | Sales 2025 * | 32.08M 43.85M | Capitalization | 135M 184M |
|---|---|---|---|---|---|
| Net income 2024 * | -125M -171M | Net income 2025 * | -120M -164M | EV / Sales 2024 * | 48.1 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.2 x |
| P/E ratio 2024 * |
-1.37
x | P/E ratio 2025 * |
-1.51
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Syros Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | -1.18% | ||
| 1 week | +11.01% | ||
| Current month | -5.79% | ||
| 1 month | -19.36% | ||
| 3 months | -26.64% | ||
| 6 months | +98.43% | ||
| Current year | -35.30% |
1 week
4.57
5.32
1 month
4.405.95
Current year
4.408.17
1 year
2.098.17
3 years
2.0970.30
5 years
2.09156.50
10 years
2.09243.75
| Managers | Title | Age | Since |
|---|---|---|---|
Conley Chee
CEO | Chief Executive Officer | 54 | 21-09-26 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 12-10-31 |
Jason Haas
DFI | Director of Finance/CFO | 56 | 21-10-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 17-06-11 | |
Tim Tyson
BRD | Director/Board Member | 71 | 22-09-15 |
Marsha Fanucci
BRD | Director/Board Member | 70 | 15-10-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.04 | -1.18% | 44,534 |
| 24-04-25 | 5.1 | +0.59% | 128,577 |
| 24-04-24 | 5.07 | -1.36% | 89,636 |
| 24-04-23 | 5.14 | +3.01% | 172,679 |
| 24-04-22 | 4.99 | +9.91% | 151,987 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.04
USD
Average target price
19.25
USD
Spread / Average Target
+281.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.30% | 135M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SYRS Stock
